Sellas Life Sciences Group I

SELLAS Life Sciences shares dropped 3.9% on Monday as the latest share count of 196.6 million suggests a $2.14 billion market cap, 14% above the live feed. The biotech awaits final REGAL trial data.

SELLAS Life Sciences shares dropped 14% on Friday amid investor caution over the REGAL Phase 3 trial timeline, testing the company's $2.2 billion market cap.

SELLAS Life Sciences rose 12.3% on Friday, closing at $13.19, with a market cap discrepancy of $319 million ahead of REGAL trial results.

SELLAS Life Sciences shares climbed 12.3% to $13.19, lifting estimated equity value by $1.62 billion since May. The REGAL trial's 80th event is pending.

SELLAS Life Sciences (SLS) surged 6.3% to $11.19 as short interest climbed to 32.65% of float and trading volume doubled. The company amended executive severance terms and disclosed 78 of 80 events reached in its Phase 3 AML trial.

SELLAS Life Sciences (SLS) surged 12.6% to $10.33 on heavy volume after an 8-K filing revealed changes to executive severance terms. The stock's implied equity value reached $2.03 billion.

SELLAS Life Sciences shares climbed 4.1% to $7.59 on Tuesday after the CEO disclosed the REGAL trial is nearing the 80-event threshold for final analysis.

SELLAS Life Sciences shares rose after hours as its REGAL leukemia trial recorded 78 of 80 events needed for final analysis. The company reported a Q1 net loss of $8.4 million but has $107.1 million in cash.